Treating Chronic Hepatitis Delta: The Need for Surrogate Markers of Treatment Efficacy

Chronic hepatitis delta represents the most severe from of chronic viral hepatitis. Its current treatment consist of the use of interferons and is largely unsatisfactory. Several new compounds are currently in development for hepatitis D virus (HDV) infection. However, surrogate markers for developing clinical endpoints in HDV infection are not well defined. The current manuscript aimed to evaluate existing data on treatment of HDV infection and to suggest treatment goals (possible “trial endpoints”) that could be used across different trials.

Source: Journal of Hepatology - December 26, 2018 Category: Gastroenterology Authors: Cihan Yurdaydin, Zaigham Abbas, Maria Buti, Markus Cornberg, Rafael Esteban, Ohad Etzion, Edward J. Gane, Robert G. Gish, Jeffrey S. Glenn, Saeed Hamid, Theo Heller, Christopher Koh, Pietro Lampertico, Yoav Lurie, Michael Manns, Raymundo Parana, Mario Riz Tags: Clinical Trial Watch Source Type: research